Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-13

Clinical Trial Update: A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating regorafenib in refractory advanced gastro-oesophageal cancer is ongoing or results not reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Regorafenib (regorafenib)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Gastro-Oesophageal Cancer | Phase 3 | Status: UNKNOWN